CIK 0001084267 · Non-accelerated filer<br>Smaller reporting company
Mobiquity Technologies, Inc.
Sign in to watch- Tickers
- MOBQ MOBQW
- Exchange
- OTC
- Industry
- Services-Advertising
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- operating
- EIN
- 113427886
- Phone
- 516-256-7766
- Business address
- 35 TORRINGTON LANE, SHOREHAM, NY, 11786
- Former names
- ACE MARKETING & PROMOTIONS INC
Securities
- MOBQ Common stock OTC
- MOBQW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-12-08 | Zurkow Peter L. Director | Grant or award · Common Stock Options | +25,000 | 25,000 | ||
| 2021-12-08 | Wright Michael A. Director | Grant or award · Common Stock Options | +25,000 | 25,000 | ||
| 2021-12-08 | Julia Dean L. CEO | Grant or award · Common Stock Options | +250,000 | 337,500 | ||
| 2021-12-08 | McDonnell Sean CFO | Grant or award · Common Stock Options | +25,000 | 28,000 | ||
| 2021-12-08 | Iacovone Anthony Director | Grant or award · Common Stock Options | +25,000 | 25,000 | ||
| 2021-12-08 | Salkind Gene Director | Grant or award · Common Stock Options | +35,000 | 1,422,500 | ||
| 2021-09-30 | Salkind Gene Director | Option exercise | +375,000 | 1,116,021 | ||
| 2021-09-30 | Salkind Gene Director | Option exercise · Preferred Stock | −1,500 | 1,012,500 | ||
| 2021-09-30 | Salkind Gene Director | Option exercise · Common Stock Purchase Warrants | +375,000 | 1,387,500 | ||
| 2021-04-01 | Salkind Gene Director | Grant or award · Notes | +150,000 | 1,684,375 | ||
| 2020-09-08 | Salkind Gene Director | Grant or award | +15,000,000 | $0.01 | $150K | 296,318,355 |
| 2020-07-21 | Salkind Gene Director | Grant or award | +15,000,000 | $0.01 | $150K | 281,318,355 |
| 2019-09-13 | Salkind Gene Director | Purchase | +35,000,000 | $0.01 | $336K | 126,318,355 |
| 2019-09-13 | Salkind Gene Director | Purchase | +127,500,000 | $0.02 | $2.4M | 253,818,355 |
| 2019-09-13 | Salkind Gene Director | Purchase | +12,500,000 | $0.04 | $500K | 266,318,355 |
| 2019-09-13 | Salkind Gene Director | Grant or award · Notes | +2,300,000 | 341,502,500 | ||
| 2019-09-13 | Salkind Gene Director | Purchase | +35,000,000 | $0.01 | $336K | 126,318,355 |
| 2019-09-13 | Salkind Gene Director | Purchase | +127,500,000 | $0.02 | $2.4M | 253,818,355 |
| 2019-09-13 | Salkind Gene Director | Purchase | +12,500,000 | $0.04 | $500K | 266,318,355 |
| 2019-09-13 | Salkind Gene Director | Grant or award · Notes | +2,300,000 | 341,502,500 |
Page 4 of 9 · 170 trades